Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, ...

Vitamin D supplementation may help manage hypertension, particularly in older adults with overweight or obesity, a new study ...

The rate of deaths from ischemic heart disease related to obesity nearly tripled in the U.S. over a two-decade span, ...

Lives lost to obesity-related heart disease have nearly tripled over the past twenty years, a new study reports.

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- A deep learning model can predict the risk for obesity for young children using ...

Despite the diverse nature of obesity, there is compelling genetic, clinical, and experimental evidence that endorses the ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Traditionally, scientists believed that obesity led to type 2 diabetes by impairing insulin signaling within liver and fat ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Adults With Obesity More Likely to Ration Drugs to Save Money. Adults with obesity are more likely to ration their ...

Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, ...